Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Liberty Global Ltd Class C (LBTYK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Liberty Global Ltd Class C — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while Liberty Global Ltd Class C trades at $10.27 (market cap $3.55B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 11.2× Liberty Global Ltd Class C's market cap. Which is the better fit depends on your goals.
| ALNY | LBTYK | |
|---|---|---|
Market Cap | $39.89B | $3.55B |
Sector | Health | Technology |
52-Week High | $491.22 | $12.67 |
52-Week Low | $278.09 | $10.07 |
Enterprise Value | $38.15B | $10.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
LBTYK trades at $10.27, down 0.29% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported a net loss of $7.14 billion for 2025, though revenue grew to $4.88 billion. Recent news highlights the planned 2027 Amsterdam listing of Ziggo Group as a key catalyst. Analyst consensus is strongly bullish with 69% buy ratings, viewing the stock as a sum-of-the-parts opportunity trading below intrinsic value.
The investment case hinges on the Ziggo Group spin-off unlocking value, with potential upside to $27 per share according to bullish analysts. However, persistent net losses, high debt, and execution risks around the listing pose significant threats. The stock offers high risk-reward for investors betting on successful corporate restructuring and operational turnaround by 2027.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Liberty Global Ltd Class C
Liberty Global is a world leader in converged broadband, video, and mobile communications. It operates large-scale fiber and 5G networks across Europe, providing essential digital services to millions of customers.
Read more on LBTYK →
